A Phase 4 interventional study of Travoprost 0.004% ophthalmic solution (TRAVATAN) and Tafluprost 0.0015% ophthalmic solution in Glaucoma, sponsored by Alcon Research. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2012-06-20.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.
Among the 42 studies testing travoprost in Glaucoma, this one is the 28th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2009, is one of 25 in phase 4, and was the 25th registered.
1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 89 across the 39 interventional studies. Of the 41 that completed or were terminated, 18 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
93 studies in Glaucoma by Alcon: none open now, none under way, none of them phase 3. Of 92 finished, 35 (38%) have results posted.
Among the 93 studies in Glaucoma by Alcon, this one is the 62nd largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2009, is one of 37 in phase 4, and was the 48th registered.
Alcon’s Glaucoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing travoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 93 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost first, with tafluprost second. Each product dosed for six weeks.
Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN) · Drug: Tafluprost 0.0015% ophthalmic solution
Tafluprost first, with travoprost second. Each product dosed for six weeks.
Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN) · Drug: Tafluprost 0.0015% ophthalmic solution
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Also known as: TRAVATAN
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Mean Intraocular Pressure (IOP) at 8:00 PM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Mean Intraocular Pressure (IOP) at 8:00 AM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Mean Intraocular Pressure (IOP) at 10:00 AM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Mean Intraocular Pressure (IOP) at 12:00 PM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Mean Intraocular Pressure (IOP) at 2:00 PM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Mean Intraocular Pressure (IOP) at 4:00 PM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Mean Intraocular Pressure (IOP) at 6:00 PM
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 6 weeks
Patients were recruited from four private practices located in Germany.
| Milestone | Travoprost-to-tafluprost | Tafluprost-to-travoprost |
|---|---|---|
| Started | 28 | 23 |
| Completed | 25 | 23 |
| Not completed | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | Travoprost-to-tafluprost | Tafluprost-to-travoprost |
|---|---|---|
| Started | 25 | 23 |
| Completed | 25 | 23 |
| Not completed | 0 | 0 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 8:00 PM | 17.1 ± 3.17 | 17.7 ± 3.23 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 8:00 AM | 17.0 ± 2.36 | 17.5 ± 2.20 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 10:00 AM | 16.7 ± 2.39 | 17.3 ± 2.50 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 12:00 PM | 16.7 ± 2.47 | 17.2 ± 2.46 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 2:00 PM | 16.9 ± 2.69 | 17.3 ± 2.77 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 4:00 PM | 17.1 ± 2.85 | 17.6 ± 2.80 |
Intraocular pressure was measured by Goldmann applanation tonometry.
| mm Hg | Travoprost | Tafluprost |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 6:00 PM | 16.9 ± 3.12 | 17.6 ± 3.13 |
Collected over Adverse events were collected for the duration of the study: 10-September-2009 to 2-March-2010.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travoprost | — | 0/51 (0%) | 0/51 (0%) |
| Tafluprost | — | 0/48 (0%) | 0/48 (0%) |
| Age Continuous(years) | Travoprost-to-tafluprost | Tafluprost-to-travoprost | Total |
|---|---|---|---|
| Mean | 69.1 ± 7.8 | 68.5 ± 10.5 | 68.8 ± 9.0 |
| Sex: Female, Male(Participants) | Travoprost-to-tafluprost | Tafluprost-to-travoprost | Total |
|---|---|---|---|
| Female | 16 | 15 | 31 |
| Male | 12 | 8 | 20 |
No study locations are listed for this record.
The record gives a start of Sep 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Travoprost · Tafluprost